Working…
COVID-19 is an emerging, rapidly evolving situation.
Get the latest public health information from CDC: https://www.coronavirus.gov.

Get the latest research information from NIH: https://www.nih.gov/coronavirus.
ClinicalTrials.gov
ClinicalTrials.gov Menu
Trial record 3 of 41 for:    cytosorb

Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19 (CYTOCOV-19)

The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.
 
ClinicalTrials.gov Identifier: NCT04344080
Recruitment Status : Recruiting
First Posted : April 14, 2020
Last Update Posted : April 14, 2020
Sponsor:
Information provided by (Responsible Party):
Universitätsklinikum Hamburg-Eppendorf

Brief Summary:
This prospective randomized single Center study investigates to what extent the physical elimination of the inflammatory mediators using the CytoSorb adsorber reduces the morbidity of severely and critically ill patients with Covid-19.

Condition or disease Intervention/treatment Phase
COVID-19 Device: CytoSorb-Therapy Not Applicable

Layout table for study information
Study Type : Interventional  (Clinical Trial)
Estimated Enrollment : 24 participants
Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: Effect of CytoSorb Adsorber on Hemodynamic and Immunological Parameters in Critical Ill Patients With COVID-19
Actual Study Start Date : April 1, 2020
Estimated Primary Completion Date : December 2020
Estimated Study Completion Date : February 2021

Arm Intervention/treatment
Active Comparator: CytoSorb-Therapy
Therapy of COVID-19 with need for extracorporeal circulation (continuous renal replacement therapy or extracorporeal membrane oxygenation) using standard of care in Addition with hemoadsorption using CytoSorb-Adsorber
Device: CytoSorb-Therapy
Additional use of Cytosorb-Adsorber in patients with COVID-19 and need for extracorporeal circulation (continuous renal replacement therapy or extracorporeal membrane oxygenation)

No Intervention: Standard of care
Therapy of COVID-19 with need for extracorporeal circulation (continuous renal replacement therapy or extracorporeal membrane oxygenation) using standard of care



Primary Outcome Measures :
  1. Percentage of patients with a significant stabilization of hemodynamics for at least 24 hours [ Time Frame: 24 hours ]
    Percentage of patients with a significant stabilization of hemodynamics ("shock reversal"), defined as a significant reduction of the noradrenaline dose (≤ 0.05 µg/kg/min) while maintaining mean arterial pressure ≥ 65 mmHg for at least 24 hours compared to control group


Secondary Outcome Measures :
  1. Change in organ dysfunction [ Time Frame: 10 days ]
    Change in organ dysfunction based on "Sequential Organ Failure Assessment" (SOFA) Score The SOFA score is made of 6 variables, each representing an organ system. Each organ system is assigned a point value from 0 (normal) to 4 (high degree of dysfunction/failure) The worst physiological variables were collected serially every 24 hours of a patient's ICU admission. The "worst" measurement was defined as the measure that correlated to the highest number of points. The SOFA score ranges from 0 to 24.

  2. Lactate clearance [ Time Frame: 10 days ]
    Improving lactate clearance by lowering serum lactate levels

  3. Renal replacement therapy [ Time Frame: 10 days ]
    Time with need for renal replacement therapy

  4. Extracorporeal Membrane Oxygenation [ Time Frame: 10 days ]
    Time with Need for Extracorporeal Membrane Oxygenation

  5. ICU length of stay [ Time Frame: 90 days ]
    ICU length of stay

  6. Time on mechanical ventilation [ Time Frame: 10 days ]
    Time on mechanical ventilation

  7. Cumulative catecholamine dose [ Time Frame: 10 days ]
    Cumulative catecholamine dose

  8. Overall and ICU mortality [ Time Frame: 90 days ]
    Overall and ICU mortality

  9. Change of plasma Interleukin-6 (IL6) level [ Time Frame: 10 days ]
    Change of plasma Interleukin-6 (IL6) level

  10. Change of plasma Interleukin-10 (IL10) level [ Time Frame: 10 days ]
    Change of plasma Interleukin-10 (IL10) level

  11. Change of plasma Procalcitonin (PCT) level [ Time Frame: 10 days ]
    Change of plasma Procalcitonin (PCT) level

  12. Change of HLA-DR level [ Time Frame: 10 days ]
    Change of HLA-DR (Human Leukocyte Antigen - DR isotype) level of monocytes

  13. Change of TNF alpha level after ex-vivo stimulation [ Time Frame: 10 days ]
    Change of TNF-alfa level (Tumor Necrosis Factor alpha) level after LPS (Lipopolysaccharides) stimulation as sign of monocytic immunocompetence



Information from the National Library of Medicine

Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the contacts provided below. For general information, Learn About Clinical Studies.


Layout table for eligibility information
Ages Eligible for Study:   18 Years to 90 Years   (Adult, Older Adult)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No
Criteria

Inclusion Criteria:

  • confirmed COVID-19 disease
  • refractory shock with need for norepinephrine ≥ 0.2 μg/kg/min for MAP ≥ 65 mmHg
  • IL6 ≥ 500 ng/l
  • Indication for CRRT or ECMO

Exclusion Criteria:

  • Liver cirrhosis Child Pugh C
  • "do not resuscitate"-order
  • expected survival due to comorbidities < 14 days
  • pregnancy or breastfeeding
  • participation in another interventional trial

Information from the National Library of Medicine

To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.

Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04344080


Contacts
Layout table for location contacts
Contact: Dominik Jarczak, MD +49 40 741035315 d.jarczak@uke.de
Contact: Axel Nierhaus, MD +49 40 741035315 nierhaus@uke.de

Locations
Layout table for location information
Germany
University Medical Center Hamburg-Eppendorf Recruiting
Hamburg, Germany
Contact: Dominik Jarczak, MD    +49 40 741035315    d.jarczak@uke.de   
Contact: Axel Nierhaus, MD    +49 40 741035315    nierhaus@uke.de   
Principal Investigator: Stefan Kluge, MD         
Sub-Investigator: Dominik Jarczak, MD         
Sub-Investigator: Axel Nierhaus, MD         
Sub-Investigator: Kevin Roedl, MD         
Sponsors and Collaborators
Universitätsklinikum Hamburg-Eppendorf
Investigators
Layout table for investigator information
Principal Investigator: Stefan Kluge, MD University Hospital Hamburg-Eppendorf, Department of Intensive Care Medicine
Layout table for additonal information
Responsible Party: Universitätsklinikum Hamburg-Eppendorf
ClinicalTrials.gov Identifier: NCT04344080    
Other Study ID Numbers: CYTOCOV-19
U1111-1250-2078 ( Registry Identifier: UTN )
DRKS00021199 ( Registry Identifier: DRKS )
First Posted: April 14, 2020    Key Record Dates
Last Update Posted: April 14, 2020
Last Verified: April 2020
Individual Participant Data (IPD) Sharing Statement:
Plan to Share IPD: No

Layout table for additional information
Studies a U.S. FDA-regulated Drug Product: No
Studies a U.S. FDA-regulated Device Product: No
Keywords provided by Universitätsklinikum Hamburg-Eppendorf:
critically ill
intensive care medicine
CytoSorb
hemoadsorption